Product Pathways - Lymphocyte Signaling
Human IL-4 Neutralizing (D20H1) Rabbit mAb #11964
|11964S||100 µg||---||In Stock||---|
|11964||carrier free and custom formulation / quantity||email request|
Already purchased this product? Write a Review.
Applications Key: N=Neutralizing
Specificity / Sensitivity
Human IL-4 Neutralizing (D20H1) Rabbit mAb binds to human IL-4 (hIL-4) and neutralizes its effects in a TF-1 cell proliferation assay. This antibody does not cross-react with mouse IL-4, human IL-13, or mouse IL-13.
Source / Purification
Monoclonal antibody is produced by immunizing animals with a recombinant hIL-4 protein.
The proliferation of TF-1 cells treated with increasing concentrations of hIL-4 #8919 was assessed. After 72 hr, cells were incubated with a tetrazolium salt and the OD450 was determined.
The ability of Human IL-4 Neutralizing (D20H1) Rabbit mAb to inhibit hIL-4-induced TF-1 cell proliferation was assessed. Cells were incubated with increasing concentrations of antibody in the presence of hIL-4 #8919 (500 pg/ml). After 72 hr, viable cells were detected by incubation with a tetrazolium salt and the OD450 was determined.
Neutralizing antibodies can be used to inhibit normal biological function through their binding to biological molecules. These reagents can be used to determine the effects that a particular molecule has in biological systems. Human IL-4 Neutralizing (D20H1) Rabbit mAb has been shown to neutralize the proliferation of TF-1 cells in vitro with an ND50 in the range of 3-19 ng/ml.
Interleukin-4 (IL-4) is produced by T cells, NK T cells, γδ cells, and mast cells (1). Target cells include B cells, T cells, and macrophages (1). IL-4 induces differentiation of naive T cells into the Th2 phenotype. IL-4 also promotes B cell proliferation, antibody isotype switching, and expression of other Th2 cytokines including IL-5 and IL-9. IL-4-induced Th2 polarization is important in developing humoral immunity against extracellular pathogens (1) and is involved in the development of allergy and asthma (2). IL-4 binds to two distinct receptors, the type I receptor and type II receptor. The type I receptor is a heterodimer consisting of IL-4Rα chain and the common gamma chain, γc (3,4). The type II receptor, which is shared with IL-13, is a heterodimer of IL-4Rα and IL-13Rα1. Signaling initiated via type I receptor results in the activation of Jak1/Stat6, Jak3, and the PI3K/Akt pathways (3). The type II receptor activates the Jak1/Stat6 and the Tyk2/Stat3 pathways (3).
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.